Semaglutide works by helping you feel full sooner and ultimately reduces the desire to eat more
Quick Answer: GLP-1 receptor agonists are associated with a modest but statistically significant increase in gallbladder disease risk, including gallstones and cholecystitis, affecting approximately 13% of users
Helps renew damaged and fosters a noticeably healthier youthful glow
Weight loss injections may lead to modest improvements in cholesterol levels, particularly reductions in total cholesterol, LDL cholesterol, and triglycerides, primarily through weight loss itself
In addition to retatrutide, a growing pipeline of emerging compounds includes other multi-agonists such as Survodutide (GLP-1/glucagon co-agonist), and Cagrilintide (a long-acting amylin analogue), all currently being evaluated in advanced clinical trials (139)
Your provider can determine whether either option may be appropriate